Merck & Co., Inc. reported strong overall revenue growth for the second quarter of 2024 on 30 July, but the company’s second-biggest seller fell short of analyst consensus due to an unexpected sales decline in China, a key growth market for the HPV vaccine Gardasil. While Merck still expects the product to reach forecasted sales of $11bn by 2030, Gardasil’s immediate growth trajectory is less clear as the company noted that its shipments into China may decline later this year.
Merck’s Strong Q2 Overshadowed By Gardasil Sales Decline In China
Revenue Guidance Raised, EPS Expectation Lowered
Merck & Co.’s $16.11bn in sales exceeded expectations and prompted a slight increase in 2024 guidance, but HPV vaccine Gardasil came in slightly below consensus due to lower sales in China.
More from Business
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.
• By
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
More from Scrip
• By
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.